Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
You may also be interested in...
People On The Move: Appointments At ANEFP, CHPA, Norgine, InfectoPharm, DSM
A round-up of the latest appointments in Europe's and the US health and wellness industries: Spain's ANEFP elects Martín as president; US CHPA appoints Parks as senior VP of regulatory and scientific affairs, Norgine hires HRA's Hilton to lead its consumer business; Infectopharm names Weleda's Ammendola as R&D head; and DSM-Firmenich makes management changes.
People On The Move: Appointments At GSK, Reckitt And Norgine
A round-up of the latest health and wellness appointments: GSK makes addition to senior management teams in Europe; Reckitt appoints general counsel; and Norgine announces CEO change.
Norgine Drives Role As Specialty Partner For Europe
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.